- From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 4: “Antibodies & Biologics × AI”) explores how AI is applied to sequence design, affinity maturation, and developability prediction, and how this differs from small-molecule use cases.
1. Why “Antibodies & Biologics × AI” Is Different from Small Molecules In Part 3, we focused on small-mole […]
- Oncology Drug Approval News Flash: Daratumumab and hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone approved for newly diagnosed multiple myeloma in transplant-ineligible adults
FDA approval summary On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved daratumumab and […]
- From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 3: “Small Molecules × AI”) walks through how AI is actually used from hit finding to lead optimization, highlighting concrete use cases, benefits, and limitations.
1. Why Small Molecules Became the Primary Testbed for AI When you scan AI-in-drug-discovery papers and case st […]
- The Word “Vaccine” Breaks the Conversation: How Far Have Cancer Vaccines Actually Come?
The moment the word “vaccine” appears, conversations tend to heat up—and then collapse. This happens in infect […]
- From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 2: “Data and Algorithms Behind AI-Driven R&D”) explains which data types AI relies on, what sources those data come from, and how representative model families are used in practice.
1. Data and Models: The Core of AI in Drug Discovery In Part 1, we mapped where AI can plug into the drug disc […]
- From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 1: “What Is AI in Drug Discovery?”) maps the entire R&D-to-market value chain and clarifies what AI can – and still cannot – do.
1. Why AI in Drug Discovery Is in the Spotlight Now “AI in drug discovery” has become a buzzword in recent yea […]
- JPM2026 Key Topics Series Part 3: How to Read CEO Remarks — Companies That Speak With Numbers vs. Companies That Signal Posture
At JPM2026, CEO remarks drew outsized attention. The reason is straightforward: professional investors already […]
- JPM2026 Key Topics Series Part 2: Why Mega-M&A Didn’t Show Up — Yet Capital and Deals Still Moved
One of the defining “feelings” at JPM2026 was that the conference was crowded and energetic—yet true mega-M&am […]
- JPM2026 Key Topics Series Part 1: Obesity & Metabolic (GLP-1) — The Battle Has Moved to Execution
At JPM2026, obesity and metabolic disease (GLP-1) remained the gravitational center of the conference. Yet the […]
- Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Series Hub)
This series places women’s cancer risk on a single life-course map—from puberty and reproductive years to preg […]